Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients.
Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients.
复制标题
DOI：
10.12659/msm.907798
复制
发表时间：
2018-05-27
期刊：
影响因子：
--
通讯作者：
Yang Y
中科院分区：
文献类型：
--
作者：
Huang Y;Wang H;Yang Y
乳腺癌（BC）患者的临床结果仍然很差。我们分析了BC微阵列研究GSE 37751、GSE 7390和GSE 21653，以研究BC患者与其正常对应者之间的FGF 5基因表达，以及FGF 5表达与年龄、肿瘤大小、组织病理学分级、雌激素受体、根据St Gallen标准的临床风险组、根据NPI标准的临床风险组、根据Veridex签名的临床风险组之间的关系，BC患者的无远处转移生存期（DMFS）、至远处转移的时间（TDM）、无病生存期（DFS）和总生存期（OS）。基因集富集分析（GSEA）被用来研究确切的机制。BC组FGF 5表达较正常对照组明显增高（P<0.0001）。与FGF 5高表达组相比，FGF 5低表达组的BC患者具有更好的临床特征，包括肿瘤大小、组织病理学分级、雌激素受体、根据St Gallen标准、NPI标准和Veridex签名的临床风险组、DMFS、TDM和DFS。GSEA结果表明，FGF 5通过紫外线反应和TGF-β信号通路抑制BC细胞增殖。定量PCR证实BC患者中FGF 5过表达。我们的研究结果表明，FGF 5是BC患者的独立保护因子。
The clinical outcome of patients with breast cancer (BC) remains poor. We analyzed BC microarray studies GSE37751, GSE7390, and GSE21653 to investigate the expression of FGF5 gene between BC patients and their normal counterparts and the relationship between FGF5 expression and age, tumor size, histopathological grading, estrogen receptors, clinical risk group according to St Gallen criteria, clinical risk group according to NPI criteria, clinical risk group according to Veridex signature, distant metastasis-free survival (DMFS), time to distant metastasis (TDM), disease-free survival (DFS), and overall survival (OS) of BC patients. Gene set enrichment analysis (GSEA) was used to investigate the exact mechanisms. FGF5 expression was significantly upregulated in BC patients relative to that in normal controls (P<0.0001). BC patients in the FGF5 low-expression group were correlated with better clinical characteristics, including tumor size, histopathological grading, estrogen receptors, clinical risk group according to St Gallen criteria, NPI criteria and Veridex signature, DMFS, TDM, and DFS compared with those in the FGF5 high-expression cohort. The result of GSEA indicated that FGF5 inhibits the proliferation of BC cells via ultraviolet response and TGF-β signaling. Quantitative PCR verified that FGF5 was overexpressed in patients with BC. Our results suggest that FGF5 is an independent protective factor for BC patients.